The nontuberculous mycobacterial infections Market is expected to experience notable growth in the coming years, driven by the increasing prevalence and improved diagnosis of NTM infections, particularly among aging populations and individuals with underlying respiratory conditions. Additionally, the expected launch of emerging therapies such as Omadacycline (NUZYRA; Paratek Pharmaceuticals), MRX-5 (MicuRx Pharmaceuticals), Epetraborole (AN2 Therapeutics), RHB-204 (Redhill Biopharma), and others will further propel market growth.
The nontuberculous mycobacterial infections Market is expected to experience notable growth in the coming years, driven by the increasing prevalence and improved diagnosis of NTM infections, particularly among aging populations and individuals with underlying respiratory conditions. Additionally, the expected launch of emerging therapies such as Omadacycline (NUZYRA; Paratek Pharmaceuticals), MRX-5 (MicuRx Pharmaceuticals), Epetraborole (AN2 Therapeutics), RHB-204 (Redhill Biopharma), and others will further propel market growth.